Keryx Biopharmaceuticals (Keryx Biopharmaceuticals) Market Cap : $404.46 Mil (As of May. 05, 2024)

View and export this data going back to 2000. Start your Free Trial

What is Keryx Biopharmaceuticals Market Cap?

Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Keryx Biopharmaceuticals's share price for the quarter that ended in Sep. 2018 was $3.4. Keryx Biopharmaceuticals's Shares Outstanding (EOP) for the quarter that ended in Sep. 2018 was 120.38 Mil. Therefore, Keryx Biopharmaceuticals's market cap for the quarter that ended in Sep. 2018 was $409.29 Mil.

Keryx Biopharmaceuticals's quarterly market cap declined from Mar. 2018 ($492.64 Mil) to Jun. 2018 ($452.63 Mil) and declined from Jun. 2018 ($452.63 Mil) to Sep. 2018 ($409.29 Mil).

Keryx Biopharmaceuticals's annual market cap increased from Dec. 2015 ($530.96 Mil) to Dec. 2016 ($620.22 Mil) but then declined from Dec. 2016 ($620.22 Mil) to Dec. 2017 ($554.23 Mil).

Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Keryx Biopharmaceuticals's Enterprise Value for Today is $510.62 Mil.

Keryx Biopharmaceuticals Market Cap Historical Data

The historical data trend for Keryx Biopharmaceuticals's Market Cap can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Keryx Biopharmaceuticals Market Cap Chart

Keryx Biopharmaceuticals Annual Data

Trend

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Market Cap

Get a 7-Day Free Trial

1,070.19

1,311.42

530.96

620.22

554.23

Keryx Biopharmaceuticals Quarterly Data
	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18
Market Cap	Get a 7-Day Free Trial															845.89	554.23	492.64	452.63	409.29

Competitive Comparison of Keryx Biopharmaceuticals's Market Cap

For the Biotechnology subindustry, Keryx Biopharmaceuticals's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Keryx Biopharmaceuticals's Market Cap Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Keryx Biopharmaceuticals's Market Cap distribution charts can be found below:

* The bar in red indicates where Keryx Biopharmaceuticals's Market Cap falls into.

Keryx Biopharmaceuticals Market Cap Calculation

Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.

Keryx Biopharmaceuticals's Market Cap for the fiscal year that ended in Dec. 2017 is calculated as

Market Cap (A: Dec. 2017 )	=	Share Price (A: Dec. 2017 )	*	Shares Outstanding (EOP) (A: Dec. 2017 )
	=	$4.65	*	119.19
	=	$554.23

Keryx Biopharmaceuticals's Market Cap for the quarter that ended in Sep. 2018 is calculated as

Market Cap (Q: Sep. 2018 )	=	Share Price (Q: Sep. 2018 )	*	Shares Outstanding (EOP) (Q: Sep. 2018 )
	=	$3.4	*	120.38
	=	$409.29

Keryx Biopharmaceuticals (NAS:KERX) Market Cap Explanation

Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.

Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.

Keryx Biopharmaceuticals Market Cap Related Terms

Thank you for viewing the detailed overview of Keryx Biopharmaceuticals's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.

Keryx Biopharmaceuticals (Keryx Biopharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Keryx Biopharmaceuticals Inc (NAS:KERX) » Definitions » Market Cap

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.keryx.com

Keryx Biopharmaceuticals Inc focuses on developing medicines to people with kidney diseases. The marketed product of the company is auryxia tablet, which is a iron based medicine.

Executives

Scott A Holmes	officer: Chief Financial Officer	C/O KERYX BIOPHARMACEUTICALS INC 1 MARINA PARK DR., 10TH FLOOR BOSTON MA 02210
Daniel Paul Regan	director	C/O INTERCEPT PHARMACEUTICALS, INC., 18 DESBROSSES ST., NEW YORK NY 10013
Jodie Pope Morrison	director, officer: Interim CEO	C/O TOKAI PHARMACEUTICALS, INC., ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142
Mark J Enyedy	director	C/O FATE THERAPEUTICS, INC., 3535 GENERAL ATOMICS COURT, SUITE 200, SAN DIEGO CA 92121
Michael Thomas Heffernan	director	C/O CORNERSTONE THERAPEUTICS INC., 1255 CRESCENT GREEN DRIVE, SUITE 250, CARY NC 27518
Steven C Gilman	director	110 HARTWELL AVENUE, LEXINGTON MA 02421
Michael W Rogers	director	C/O KERYX BIOPHARMACEUTICALS INC, ONE MARINA PARK DRIVE, BOSTON MA 02210
Baupost Group Gp, L.l.c.	10 percent owner	10 ST. JAMES AVENUE, SUITE 1700, BOSTON MA 02116
Baupost Group Llc/ma	director, 10 percent owner	10 ST JAMES AVE, SUITE 1700, BOSTON MA 02116
Seth A Klarman	10 percent owner	10 ST JAMES AVENUE, STE 1700, BOSTON MA 02116
Greg Madison	director, officer: President and CEO	ONE MARINA PARK DRIVE LEXINGTON MA 02210
Brian Adams	officer: General Counsel and Secretary	750 LEXINGTON AVENUE, NEW YORK NY 10022
John P. Butler	director	C/O RELYPSA, INC., 700 SAGINAW DR., REDWOOD CITY CA 94063
Sak Corp	10 percent owner	10 ST JAMES AVENUE, STE 1700, BOSTON MA 02116
Oliviero James F Iii	officer: Chief Financial Officer	C/O KERYX BIOPHARMACEUTICALS, INC., 750 LEXINGTON AVENUE, NEW YORK NY 10022